Why antibodies, you ask? Well, they’re the superheroes in battling all sorts of serious diseases, and the cool part? They come with fewer side effects compared to the old-school treatments. IBM and Boehringer Ingelheim are essentially hoping to revolutionize the antibody game by creating a solid AI model. The goal? Make the production of life-saving treatments a breeze, scalable and super-efficient.
